$ARCT
Arcturus Therapeutics Holdings Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024123469 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $41.67M
YoY Change -7.68%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $13.28M
YoY Change -0.93%
% of Gross Profit
Research & Development $39.13M
YoY Change -23.38%
% of Gross Profit
Depreciation & Amortization $912.0K
YoY Change 11.22%
% of Gross Profit
Operating Expenses $52.41M
YoY Change -18.69%
Operating Profit -$10.74M
YoY Change -44.41%
Interest Expense $3.617M
YoY Change -9.58%
% of Operating Profit
Other Income/Expense, Net $3.818M
YoY Change -4.09%
Pretax Income -$7.120M
YoY Change -53.55%
Income Tax -$200.0K
% Of Pretax Income
Net Earnings -$6.903M
YoY Change -57.45%
Net Earnings / Revenue -16.56%
Basic Earnings Per Share -$0.26
Diluted Earnings Per Share -$0.26
COMMON SHARES
Basic Shares Outstanding 27.09M 27.04M
Diluted Shares Outstanding 27.06M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $237.2M
YoY Change -23.96%
Cash & Equivalents $237.2M
Short-Term Investments
Other Short-Term Assets $63.44M
YoY Change 47.2%
Inventory
Prepaid Expenses
Receivables $30.20M
Other Receivables $0.00
Total Short-Term Assets $330.8M
YoY Change -15.88%
LONG-TERM ASSETS
Property, Plant & Equipment $10.35M
YoY Change -18.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.885M
YoY Change -91.47%
Total Long-Term Assets $39.83M
YoY Change -38.13%
TOTAL ASSETS
Total Short-Term Assets $330.8M
Total Long-Term Assets $39.83M
Total Assets $370.7M
YoY Change -19.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.13M
YoY Change -44.83%
Accrued Expenses $32.40M
YoY Change 13.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $69.46M
YoY Change -20.78%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change -100.0%
Other Long-Term Liabilities $39.33M
YoY Change 3929.2%
Total Long-Term Liabilities $39.33M
YoY Change 87.48%
TOTAL LIABILITIES
Total Short-Term Liabilities $69.46M
Total Long-Term Liabilities $39.33M
Total Liabilities $108.8M
YoY Change -38.74%
SHAREHOLDERS EQUITY
Retained Earnings -$418.8M
YoY Change 17.57%
Common Stock $27.00K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $261.9M
YoY Change
Total Liabilities & Shareholders Equity $370.7M
YoY Change -19.01%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$6.903M
YoY Change -57.45%
Depreciation, Depletion And Amortization $912.0K
YoY Change 11.22%
Cash From Operating Activities -$23.76M
YoY Change -26.68%
INVESTING ACTIVITIES
Capital Expenditures $80.00K
YoY Change -91.84%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$80.00K
YoY Change -91.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 693.0K
YoY Change -96.83%
NET CHANGE
Cash From Operating Activities -23.76M
Cash From Investing Activities -80.00K
Cash From Financing Activities 693.0K
Net Change In Cash -23.15M
YoY Change 100.44%
FREE CASH FLOW
Cash From Operating Activities -$23.76M
Capital Expenditures $80.00K
Free Cash Flow -$23.84M
YoY Change -28.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001768224
CY2024Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38942
dei Entity Registrant Name
EntityRegistrantName
ARCTURUS THERAPEUTICS HOLDINGS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0595345
dei Entity Address Address Line1
EntityAddressAddressLine1
10628 Science Center Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
900-2660
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ARCT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27087359
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
237178000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
292005000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
55000000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
55000000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
30199000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32064000
CY2024Q3 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
8444000
CY2023Q4 arct Prepaid Expenses And Other Receivables
PrepaidExpensesAndOtherReceivables
7521000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
330821000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
386590000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10350000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12427000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27598000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28500000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2024Q3 us-gaap Assets
Assets
370654000
CY2023Q4 us-gaap Assets
Assets
429402000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10131000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5279000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32396000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31881000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
26936000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
44829000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
69463000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
81989000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
13338000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
42496000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25987000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25907000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
497000
CY2024Q3 us-gaap Liabilities
Liabilities
108788000
CY2023Q4 us-gaap Liabilities
Liabilities
150889000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27084000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27084000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26828000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26828000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
27000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
680641000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
646352000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-418802000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367866000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
261866000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
278513000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
370654000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429402000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
41673000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45140000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
129544000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
135944000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39134000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51077000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
151376000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155513000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13276000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13377000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40443000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40364000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
52410000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
64454000
us-gaap Operating Expenses
OperatingExpenses
191819000
us-gaap Operating Expenses
OperatingExpenses
195877000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10737000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-19314000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62275000
us-gaap Operating Income Loss
OperatingIncomeLoss
-59933000
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-201000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
4000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-642000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-175000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3818000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3981000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11981000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
9710000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7120000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15329000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-50936000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16445000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-217000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
893000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1573000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6903000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16222000
us-gaap Net Income Loss
NetIncomeLoss
-50936000
us-gaap Net Income Loss
NetIncomeLoss
-18018000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.68
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.68
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27062000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27062000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26574000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26574000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26970000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26970000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26559000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26559000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6903000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16222000
us-gaap Net Income Loss
NetIncomeLoss
-50936000
us-gaap Net Income Loss
NetIncomeLoss
-18018000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6903000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16222000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-50936000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18018000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
278513000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-26817000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10088000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2188000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
263972000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-17216000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9424000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2403000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
258583000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-6903000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9493000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2024Q3 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
682000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
261866000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
270312000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
50754000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8182000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
329248000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-52550000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8383000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
94000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
285175000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-16222000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9269000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1231000
CY2023Q3 arct Stock Issued During Period Value Under Equity Plan
StockIssuedDuringPeriodValueUnderEquityPlan
609000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
280062000
us-gaap Net Income Loss
NetIncomeLoss
-50936000
us-gaap Net Income Loss
NetIncomeLoss
-18018000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2725000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2142000
us-gaap Share Based Compensation
ShareBasedCompensation
29005000
us-gaap Share Based Compensation
ShareBasedCompensation
25834000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-643000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-90000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
33953000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-502000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1865000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
35456000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
923000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-556000
arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-3638000
arct Increase Decrease Operating Lease Right Of Use Asset
IncreaseDecreaseOperatingLeaseRightOfUseAsset
-3011000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4852000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10497000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-625000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3437000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-47051000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
33960000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2656000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-3198000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-59463000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17470000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
648000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2026000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-648000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2026000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4602000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1325000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
682000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
609000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
20000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
27364000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5284000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5430000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-54827000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24926000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
348890000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
393977000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294063000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
369051000
us-gaap Interest Paid Net
InterestPaidNet
2102000
arct Non Cash Asset Disposal
NonCashAssetDisposal
473000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2736000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
416000
arct Covid Vaccination Age Limit
CovidVaccinationAgeLimit
adults 18 years and older
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-418800000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-367900000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294100000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
237178000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
311918000
CY2024Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
55000000
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
35000000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1885000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
22133000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
294063000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
369051000
us-gaap Dividends
Dividends
0
us-gaap Dividends
Dividends
0
CY2023Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
32064000
arct Contract With Customer Asset Additions
ContractWithCustomerAssetAdditions
83375000
arct Contract With Customer Asset Deductions
ContractWithCustomerAssetDeductions
-85240000
CY2024Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
30199000
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
87325000
arct Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
82493000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
-129544000
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40274000
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21342000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21167000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10992000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8740000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10350000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12427000
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2700000
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
800000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2100000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10846000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5918000
CY2024Q3 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
7109000
CY2023Q4 arct Accrued Cystic Fibrosis Foundation Liability
AccruedCysticFibrosisFoundationLiability
7633000
CY2023Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
641000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3435000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4309000
CY2024Q3 arct Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
2039000
CY2023Q4 arct Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
2333000
CY2024Q3 arct Vinbiocare Contractual Liabilities
VinbiocareContractualLiabilities
2036000
CY2023Q4 arct Vinbiocare Contractual Liabilities
VinbiocareContractualLiabilities
2514000
CY2024Q3 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
6931000
CY2023Q4 arct Other Accrued Research And Development Expenses
OtherAccruedResearchAndDevelopmentExpenses
8533000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32396000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
31881000
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
700000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1100000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1200000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
800000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9493000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9269000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29005000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
25834000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
900000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1213000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4811000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5274000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4132000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3822000
CY2024Q3 arct Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
15750000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
35002000
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5580000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
29422000
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y4M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.047
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1300000
us-gaap Operating Lease Cost
OperatingLeaseCost
4100000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1400000
us-gaap Operating Lease Cost
OperatingLeaseCost
4200000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-123469-index-headers.html Edgar Link pending
0000950170-24-123469-index.html Edgar Link pending
0000950170-24-123469.txt Edgar Link pending
0000950170-24-123469-xbrl.zip Edgar Link pending
arct-20240930.htm Edgar Link pending
arct-20240930.xsd Edgar Link pending
arct-ex10_36.htm Edgar Link pending
arct-ex31_1.htm Edgar Link pending
arct-ex31_2.htm Edgar Link pending
arct-ex32_1.htm Edgar Link pending
arct-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img165162168_0.jpg Edgar Link pending
img165162168_1.jpg Edgar Link pending
img165162168_2.jpg Edgar Link pending
img267166769_0.jpg Edgar Link pending
img267166769_1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
arct-20240930_htm.xml Edgar Link completed
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending